ArticleThe journal of headache and pain2021
Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study.
Article in The journal of headache and pain, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 42 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neurophysiological, Biomolecular and Psychological Aspects of Erenumab Treatment in Chronic Migraine: an Open Label, Hypothesis Generator Study
Study of Early MIDAS Reduction at 3 Months as Predictor of Long-term Erenumab Treatment in Chronic Migraine: a Real-life, Open-label, Trial
Who cites it
42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 64 citations in OpenAlex.
- Psychosocial factors as predictors of headache chronification: A systematic review and meta-analysis of longitudinal studies.Headache · 2026Pooled it
- Personality in Chronic Headache: A Systematic Review with Meta-Analysis.Pain research & management · 2023Pooled it
- Cutaneous allodynia as predictor for treatment response in chronic migraine: a cohort study.The journal of headache and pain · 2023Trial
- Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial.The journal of headache and pain · 2022Trial
- Persistence and Reasons for Treatment Discontinuation of Anti-CGRP Therapies in Migraine Prophylaxis: A Systematic Review and Meta-analysis of Real-World Studies.Pain and therapy · 2026Review
- Cross-response to Calcitonin Gene-Related Peptide monoclonal antibodies in a real-world setting: analysis of prospective data collected in the French FHU InovPain registry.The journal of headache and pain · 2026Article
- Exploring the Impact of Personality Traits on Response to Anti-CGRP Therapies: Insights from a Pilot Study.NeuroSci · 2026Article
- Changes in interictal cerebral blood flow observed in migraine patients who respond to anti-calcitonin gene-related peptide therapy.Scientific reports · 2026Observational
- Psychological Subtypes and Intervention Strategies in Burning Mouth Syndrome: A Narrative Review.Journal of pain research · 2026Review
- Characteristics and management of headache among psychiatric outpatients at a Japanese general hospital: A retrospective study with an exploratory CGRP case series.PCN reports : psychiatry and clinical neurosciences · 2025Article
- Evaluation of Personality Profiles in Cluster Headache Patients: A Comparative Analysis with Migraine Patients Using the Minnesota Multiphasic Personality Inventory-3.Journal of clinical medicine · 2025Article
- Pain Coping in Patients With Chronic Migraine and Medication Overuse Headache.Brain and behavior · 2025Article
- Variation in Subtypes of Obsessive-Compulsive Traits in Migraine Patients Undergoing Onabotulinum Toxin A Therapy.Toxins · 2025Article
- Relationship Between Perceived Stress, Resilience, Mental Health, and Pain in Women with Migraines, a Case-Control Study.Journal of pain research · 2025Article
- Profiling chronic migraine patients according to clinical characteristics: a cluster analysis approach.Frontiers in neurology · 2025Article
- Role of Psychological Factors in Migraine.Cureus · 2024Review
- Application of Artificial Intelligence in the Headache Field.Current pain and headache reports · 2024Review
- A path to better quality of life in migraine: The biopsychosocial approach.Dusunen adam : Bakirkoy Ruh ve Sinir Hastaliklari Hastanesi yayin organi · 2024Article
- A Narrative Review of Intestinal Microbiota's Impact on Migraine with Psychopathologies.International journal of molecular sciences · 2024Review
- Theory of mind in chronic migraine with medication overuse assessed with the MASC.Scientific reports · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMonoclonal antibodies (mABs) targeting the calcitonin gene-related peptide (CGRP) pathway represent the first disease-specific preventive migraine therapy. Growing evidence suggests that they are effective in the preventive treatment of difficult-to-treat patients. In this study, we evaluated the psychological predictors of the outcome of treatment with the anti-CGRP monoclonal antibody erenumab in patients with chronic migraine (CM).
methodsSeventy-five patients with CM who had already failed at least 3 preventive therapies received erenumab every 28 days for a period of 12 months. Before the first administration, patients received a full psychological evaluation using The Structured Clinical Interview for DSM-5 Clinician Version (SCID-5-CV) to assess personality disturbances (primary outcome), mood and anxiety disorders, and as well specific questionnaires to evaluate alexithymia traits, childhood traumas, and current stressors (secondary outcomes).
resultsAfter 12 months of treatment, 53 patients reported a reduction of at least 50% in headache days/per month (Responders), whereas 22 did not (Non Responders). When compared to Responders, Non Responders were characterized by a higher prevalence of personality disorders belonging to Cluster C (avoidant, dependent, and obsessive-compulsive) (77% vs 37%, p = .001). Non Responders were also characterized by a higher prevalence of anxiety disorders (90% vs 60%, p = 0.007), showed more alexithymic traits (51.7 ± 13.7 vs 42.9 ± 14.3, p = 0.017), and reported a higher number of 'at least serious' current stressors (3.2 ± 4.0 vs 0.8 ± 1.4, p < .0001) than Responders. At the multivariate analysis, higher prevalence of Cluster C personality disorders (OR 3.697; p = 0.05) and higher number of 'at least serious' life events (OR 1.382; p = 0.017) arose as prognostic factors of erenumab failure.
conclusionsErenumab confirmed its effectiveness in a population of difficult-to-treat migraine. The presence of "anxious-fearful" personality together with current stressors and anxiety represent negative predictors of treatment outcome.
trial registrationThe study protocol was registered at clinicaltrials.gov ( NCT04361721 ).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.